Want to see IN:WANBURY full AI Analyst Report?
WANBURY Stock Chart & Stats
₹332.50
-₹2.65(-0.80%)
At close: 4:00 PM EDT
₹332.50
-₹2.65(-0.80%)
Day’s Range― - ―
52-Week Range₹162.00 - ₹360.00
Previous CloseN/A
Volume188.34K
Average Volume (3M)15.14K
Market Cap
₹6.95B
Enterprise Value₹9.96K
Total Cash (Recent Filing)₹76.32M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)11.4
Beta1.78
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.2%
Share Statistics
EPS (TTM)17.29
Shares Outstanding34,966,927
10 Day Avg. Volume21,456
30 Day Avg. Volume15,138
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.96
Price to Sales (P/S)1.10
P/FCF Ratio-12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.2
Revenue Forecast (FY)₹8.76B
Bulls Say, Bears Say
Bulls Say
Revenue ExpansionContinued revenue expansion indicates that Wanbury is maintaining demand across its pharmaceutical activities despite year-to-year variability. A larger revenue base can support operating scale, broaden the platform for formulations and APIs, and provide a foundation for sustained earnings improvement.
Profitability TurnaroundThe recovery from a FY2023 loss to solid operating and net margins demonstrates meaningful improvement in reported profitability. If maintained, stronger earnings can improve internal funding capacity, support investment in the business, and increase resilience compared with the earlier loss-making period.
Restored Positive EquityThe return from negative equity to a positive and expanding equity position represents a durable strengthening of the capital base. This provides a better foundation for continued operations and reduces the balance-sheet weakness associated with the company’s earlier financial position.
Bears Say
Weak Cash ConversionMinimal operating cash flow despite healthy reported income indicates that accounting profits are not converting reliably into cash. Deeply negative free cash flow can increase dependence on external funding and constrain the company’s ability to finance growth, investment, or obligations internally.
Elevated LeverageDebt materially exceeding equity leaves Wanbury more exposed to refinancing pressure, interest obligations, and earnings volatility than a company with a cleaner capital structure. Elevated leverage also limits financial flexibility if cash generation remains weak or operating conditions deteriorate.
Margin InstabilityYear-to-year margin volatility and recent gross-margin compression raise questions about the durability of the profitability turnaround. Inconsistent cost control or gross-profit retention could reduce earnings quality and make future results less predictable even while revenue continues to grow.
Wanbury Limited News
WANBURY FAQ
What was Wanbury Limited’s price range in the past 12 months?
Wanbury Limited lowest stock price was ₹162.00 and its highest was ₹360.00 in the past 12 months.
What is Wanbury Limited’s market cap?
Wanbury Limited’s market cap is ₹6.95B.
When is Wanbury Limited’s upcoming earnings report date?
Wanbury Limited’s upcoming earnings report date is Oct 15, 2026 which is in 12 days.
How were Wanbury Limited’s earnings last quarter?
Wanbury Limited released its earnings results on Aug 11, 2026. The company reported ₹0.928 earnings per share for the quarter.
Is Wanbury Limited overvalued?
According to Wall Street analysts Wanbury Limited’s price is currently Overvalued.
Does Wanbury Limited pay dividends?
Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 1.2%. See more information on Wanbury Limited dividends here
What is Wanbury Limited’s EPS estimate?
Wanbury Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanbury Limited have?
Wanbury Limited has 34,966,927 shares outstanding.
What happened to Wanbury Limited’s price movement after its last earnings report?
Wanbury Limited reported an EPS of ₹0.928 in its last earnings report. Following the earnings report the stock price went up 2.779%.
Which hedge fund is a major shareholder of Wanbury Limited?
Currently, no hedge funds are holding shares in IN:WANBURY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wanbury Limited
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulations addresses numerous therapeutic areas, including women's health, bone and joint conditions, hematological disorders, diabetes management, nutritional support, gastrointestinal ailments, post-stroke recovery, infectious diseases, respiratory issues, inflammatory conditions, pain relief, and general medicine, marketed under approximately 70 different brands. Additionally, Wanbury supplies APIs vital for medicines treating diabetes, pain, depression, allergies, inflammation, arthritis, thrombosis, epilepsy, and hypertension. The company extends its reach beyond India through product exports. Originally incorporated in 1988 as Pearl Organics Limited, the firm was rebranded as Wanbury Limited in 2004 and maintains its corporate headquarters in Navi Mumbai, India.
Technical Analysis
Jagsonpal Pharmaceuticals Ltd.
―
Kilitch Drugs (India) Limited
―
Lincoln Pharmaceuticals Ltd
―
Zim Laboratories Ltd.
―
Anuh Pharma Limited
―